Reviewer's report

Title: A pooled analysis of injection site-related adverse events in patients with schizophrenia treated with olanzapine long-acting injection

Version: 1 Date: 7 July 2013

Reviewer: JOSHUA KANTROWITZ

Reviewer's report:

This report of the adverse events to olanzapine long-acting injection is of moderate interest, but the limited focus, as described below reduced my enthusiasm. As written, it seems to suggest that injection site reactions are the only adverse reactions of note. If the limited focus on injection site reactions is to be maintained, a more systematic comparison to other long acting preparations should be included so that the reader can have some context.

Specifically, I had some concerns about the limited focus on the most serious side effect (olanzapine long-acting injection) and moreover, the lack of formal pain assessment and limited focus on adverse events titled "injection site."

The authors presumably had access to all adverse event reports, and I would be more convinced if a manual search was conducted to ensure nothing was missed. I was unclear as to why the focus was limited to injection site AE’s, it is possible that other AE's such as sedation or weight gain would also affect the risk benefit profile of this medication.

Level of interest: An article of limited interest

Quality of written English: Acceptable

Statistical review: No, the manuscript does not need to be seen by a statistician.

Declaration of competing interests:

I declare that I have no competing interests